
|Videos|May 8, 2020
Expanding Options for Treatment of CLL Using BTK Inhibitors
Author(s)Targeted Oncology
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5


















